Your browser doesn't support javascript.
loading
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.
Gevaert, Philippe; Saenz, Rebecca; Corren, Jonathan; Han, Joseph K; Mullol, Joaquim; Lee, Stella E; Ow, Randall A; Zhao, Rui; Howard, Monet; Wong, Kit; Islam, Lutaf; Ligueros-Saylan, Monica; Omachi, Theodore A; Bachert, Claus.
Afiliación
  • Gevaert P; Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium.
  • Saenz R; Genentech, Inc, South San Francisco, Calif. Electronic address: saenz.rebecca@gene.com.
  • Corren J; Departments of Medicine and Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, Calif.
  • Han JK; Eastern Virginia Medical School, Norfolk, Va.
  • Mullol J; Rhinology Unit & Smell Clinic, ENT Department, Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.
  • Lee SE; Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.
  • Ow RA; Sacramento Ear, Nose and Throat Surgical and Medical Group, Inc, Sacramento, Calif.
  • Zhao R; Genentech, Inc, South San Francisco, Calif.
  • Howard M; Roche, Mississauga, Ontario, Canada.
  • Wong K; Genentech, Inc, South San Francisco, Calif.
  • Islam L; Roche, Welwyn Garden City, United Kingdom.
  • Ligueros-Saylan M; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
  • Omachi TA; Genentech, Inc, South San Francisco, Calif.
  • Bachert C; Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium; Division of ENT Diseases, CLINTEC, Karolinska Institute, Stockholm, Sweden; First Affiliated Hospital, Sun Yat-sen University, International Airway Research Center, Guangzhou, China.
J Allergy Clin Immunol ; 149(3): 957-965.e3, 2022 03.
Article en En | MEDLINE | ID: mdl-34530020
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Pólipos Nasales / Omalizumab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Humans Idioma: En Revista: J Allergy Clin Immunol Año: 2022 Tipo del documento: Article País de afiliación: Bélgica
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Pólipos Nasales / Omalizumab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Humans Idioma: En Revista: J Allergy Clin Immunol Año: 2022 Tipo del documento: Article País de afiliación: Bélgica